Division of Rheumatology, Department of Internal Medicine, Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, Texas.
Research and Development, INOVA Diagnostics, San Diego, California.
Semin Thromb Hemost. 2014 Mar;40(2):172-7. doi: 10.1055/s-0033-1364207. Epub 2014 Jan 27.
The measurement of antiphospholipid antibodies (aPL) has been an important aspect of antiphospholipid syndrome (APS) characterization since the disease was first described in the 1980s. Despite significant efforts geared toward the standardization of immunoassays that measure anticardiolipin antibodies and anti-β2-glycoprotein I spanning three decades, there are still reports of significant interassay and interlaboratory variation in the results of these assays. At the recent 13th International Congress on Antiphospholipid Antibodies (APLA 2010, April 13-16, 2010, Galveston, TX), a task force composed of internationally recognized experts in the field of APS was formed to address these issues. In this review, we discuss approaches that have been used in the past to achieve harmonization among aPL immunoassays as well as the ongoing efforts of the APLA task force. Our review also highlights the importance of cutoff determination in aPL assays and the clinical significance of positive aPL results of varying magnitudes.
自 20 世纪 80 年代首次描述抗磷脂综合征（APS）以来，抗磷脂抗体（aPL）的检测一直是 APS 特征描述的一个重要方面。尽管人们做出了巨大的努力来规范测定抗心磷脂抗体和抗β2-糖蛋白 I 的免疫测定法，但这些测定法的结果在不同的实验室内和实验之间仍然存在显著差异。在最近的第 13 届国际抗磷脂抗体大会（APLA 2010，2010 年 4 月 13 日至 16 日，德克萨斯州加尔维斯顿）上，成立了一个由 APS 领域国际公认的专家组成的工作组来解决这些问题。在这篇综述中，我们讨论了过去在 aPL 免疫测定中实现协调一致的方法，以及 APLA 工作组正在进行的努力。我们的综述还强调了确定 aPL 测定法的临界值的重要性，以及不同程度的阳性 aPL 结果的临床意义。
